EUPATI celebrates its 5th Anniversary in Brussels by staging a free workshop.
As the fifth anniversary of the European Patients’ Academy (EUPATI) approaches, the organization is getting to stage a free workshop, “All Aboard to a Better Health Future”, to be held in Brussels on December 14th.
According to a statement from EUPATI, “Patient involvement in medicines research and development is a major driving force for transformational change in healthcare and the development of innovative medicines. This is why the EUPATI Project is such an exciting and unique opportunity – offering patients and patient advocates education and information on how new therapies are being developed and regulated.”
EUPATI works at the national level, implementing initiatives in 18 countries. The national teams offer workshops and tutorials for patient groups, interacting with professionals from clinical research, ethics committees, regulators, and the pharmaceutical industry.
“The challenge now is to bring all these initiatives and experiences together to create value for everyone. For the patient this means better understanding of research and innovation, leading to better therapies and eventually to improved health and well being,” EUPATI noted.
EUPATI is a pan-European Innovative Medicines Initiative (http://www.imi.europa.eu/) project of 33 organizations, led by the European Patients’ Forum, with partners from patient organizations (the European Genetic Alliance, the European AIDS Treatment Group, and EURORDIS), universities and not-for-profit organizations, along with a number of pharmaceutical companies.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.